98%
921
2 minutes
20
Aims: The current work describes the development of mechanistic vaginal absorption and metabolism model within Simcyp Simulator to predict systemic concentrations following vaginal application of ring and gel formulations.
Methods: Vaginal and cervix physiology parameters were incorporated in the model development. The study highlights the model assumptions including simulation results comparing systemic concentrations of 5 different compounds, namely, dapivirine, tenofovir, lidocaine, ethinylestradiol and etonogestrel, administered as vaginal ring or gel. Due to lack of data, the vaginal absorption parameters were calculated based on assumptions or optimized. The model uses release rate/in vitro release profiles with formulation characteristics to predict drug mass transfer across vaginal tissue into the systemic circulation.
Results: For lidocaine and tenofovir vaginal gel, the predicted to observed AUC and C ratios were well within 2-fold error limits. The average fold error (AFE) and absolute AFE indicating bias and precision of predictions range from 0.62 to 1.61. For dapivirine, the pharmacokinetic parameters are under and overpredicted in some studies due to lack of formulation composition details and relevance of release rate used in ring model. The predicted to observed AUC and C ratios were well within 2-fold error limits for etonogestrel and ethinylestradiol vaginal ring (AFEs and absolute AFEs from 0.84 to 1.83).
Conclusion: The current study provides first of its kind physiologically based pharmacokinetic framework integrating physiology, population and formulation data to carry out in silico mechanistic vaginal absorption studies, with the potential for virtual bioequivalence assessment in the future.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/bcp.16029 | DOI Listing |
Drug Dev Ind Pharm
September 2025
Department of Pharmaceutics, Mallige College of Pharmacy, Silvepura, Bangalore -560090.
ObjectivesThis review aims to explore gelling drug delivery systems with emphasis on formulation strategies, gelation mechanisms, administration routes, and therapeutic benefits. It also seeks to understand the role of different polymers in achieving optimal gelation and drug release profiles. Additionally, the review aims to identify current research gaps and highlight potential areas for future development and clinical translation.
View Article and Find Full Text PDFDrug Deliv
December 2025
School of Pharmacy, Queen's University Belfast, Belfast, UK.
Silicone elastomers based on polydimethylsiloxane are biocompatible and non-biodegradable thermosetting polymers used in various drug delivery applications, including subdermal implants, vaginal rings, and intrauterine devices. Without exception, all marketed silicone elastomer drug delivery products provide sustained or controlled release of highly hydrophobic small drug molecules, since drug solubility in the silicone matrix is a prerequisite for molecular diffusion and release. We are interested in developing multipurpose silicone elastomer vaginal rings for local administration of metal ions-such as copper and zinc-for non-hormonal contraception and antimicrobial therapy.
View Article and Find Full Text PDFStroke
August 2025
Department of Cardiology, Copenhagen University Hospital-Herlev and Gentofte, Denmark. (K.G.H., C.E.-L., N.D.J., M.C.H.L., K.G.S., G.G., T.B.-S., D.M.).
Background: Systemic estrogen replacement therapy is contraindicated in women with a history of ischemic stroke due to the risk of stroke recurrence. There are currently no published data available describing the association between vaginal estrogen use and recurrent ischemic stroke in women with a history of ischemic stroke. This study aimed to examine the association between vaginal estradiol tablet use and the rate of recurrent ischemic stroke in women with a history of ischemic stroke.
View Article and Find Full Text PDFJ Pharm Pharmacol
September 2025
Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innrain 80-82, 6020 Innsbruck, Austria.
Vaginal drug delivery has gained significant interest due to its numerous advantages, such as good blood flow, bypassing the first-pass effect, low systemic side effects, and potential for sustained release of pharmaceuticals. Initially targeting contraception and local effects from antibacterial, antifungal, and antiviral agents, recent advancements have broadened its scope. Notably, microbicide formulations showed promise against sexually transmitted diseases, offering superior protection and effective hormone therapies due to the vagina's large surface area and high permeability.
View Article and Find Full Text PDF